The global market for female infertility treatments is poised to achieve significant growth, projected to reach $2.33 billion by 2033 with a compound annual growth rate (CAGR) of 3.5%. This forecast comes from GlobalData’s latest report, “Female Infertility: Seven Market Drug Forecast and Market Analysis,” attributing the expansion primarily to a rising trend among women to delay pregnancy until later stages of life, when fertility typically diminishes.
The report highlights that the introduction of new therapies will contribute incrementally to this growth trajectory. Despite a competitive landscape dominated by off-label therapies—many originally developed for breast cancer and other gynecological conditions—the market remains relatively concentrated with a handful of established companies vying for market share.
Shireen Mohammad, Senior Cardiovascular & Metabolic Disorders Analyst at GlobalData, underscored the market dynamics, noting, “The development of non-injectable medications is a critical unmet need in female infertility treatments. Such innovations promise enhanced patient convenience, compliance, and overall treatment experience compared to conventional methods like in vitro fertilization (IVF).
Mohammad further predicted that a novel, easily administered drug with efficacy on par with current options could potentially disrupt the market. “Improving the route of administration to mitigate adverse effects associated with current intramuscular and vaginal methods is crucial,” Mohammad added.
The future of the female infertility market hinges significantly on advancements in therapeutic options that address these evolving patient needs while navigating regulatory challenges and competitive pressures.
Related Links:
